Triple-negative breast cancer (TNBC) is clinically defined by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and lack of overexpression/amplification of human epidermal growth factor receptor-2 (HER2) proteins or HER2 gene copies. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.